Rapid identification of early infections in febrile patients after CD19 target CAR-T cell therapy for B-cell malignancies.
Lian-Fang PuHui-Min ZhengXiang-Jiang FengAlice CharwudziXue LiangLin-Hui HuYang-Yang DingZe-Lin LiuYa LiaoShu-Dao XiongPublished in: Journal of translational medicine (2024)
CRS and prior allogeneic HCT are independent infection risk factors post-CTI in febrile B-cell malignancy patients. Our identification of novel models using PCT and CRP for predicting infection, and PCT and CRS for predicting severe infection, offers potential to guide therapeutic decisions and enhance the efficacy of CAR-T cell therapy in the future.
Keyphrases
- cell therapy
- end stage renal disease
- ejection fraction
- risk factors
- newly diagnosed
- chronic kidney disease
- stem cells
- mesenchymal stem cells
- prognostic factors
- bone marrow
- stem cell transplantation
- low dose
- cell death
- urinary tract infection
- climate change
- cell proliferation
- quantum dots
- current status
- bioinformatics analysis
- chemotherapy induced